🇺🇸 FDA

Company profile · Sponsor

NEUROCRINE

NEUROCRINE BIOSCIENCES INC

NBIX · NYSE biotech SAN DIEGO, CA, USA
Pipeline
24
Drugs
2
Patents
8

Quick answer

NEUROCRINE (NBIX) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

Company facts

Ticker NBIX
Exchange NYSE
Company type biotech
Headquarters SAN DIEGO, CA, USA
SEC CIK 0000914475

Pipeline (24)

Search pipeline →

  1. Chronocort®

    NEUROCRINE

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    5 trials

  2. Crinecerfont

    NEUROCRINE

    Congenital Adrenal Hyperplasia

    phase 3 small molecule active

    4 trials

  3. Crinecerfont placebo for oral solution, NBI-74788, NBI-74788, Crinecerfont placebo for oral Capsules

    NEUROCRINE

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  4. Hydrocortisone

    NEUROCRINE

    Congenital Adrenal Hyperplasia

    phase 3 small molecule completed

    2 trials

  5. Identical to NBI-1065845 tablets without active drug, NBI-1065845

    NEUROCRINE

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  6. Indiplon

    NEUROCRINE

    Insomnia

    phase 3 small molecule terminated

    1 trial

  7. Infacort®

    NEUROCRINE

    Adrenal Insufficiency

    phase 3 small molecule completed

    4 trials

  8. NBI-1065845

    NEUROCRINE

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  9. NBI-1065845

    NEUROCRINE

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  10. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  11. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  12. NBI-1065845, Identical to NBI-1065845 tablets without active drug

    NEUROCRINE

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  13. NBI-1117568

    NEUROCRINE

    Schizophrenia

    phase 3 small molecule active

    5 trials

  14. NBI-1117568, NBI-1117568

    NEUROCRINE

    Schizophrenia, Schizophrenia

    phase 3 small molecule active

    1 trial

  15. NBI-1117568, NBI-1117568, NBI-1117568 Placebo Capsule

    NEUROCRINE

    Schizophrenia

    phase 3 small molecule active

    1 trial

  16. NBI-34060

    NEUROCRINE

    Insomnia

    phase 3 small molecule terminated

    1 trial

  17. NBI-74788, Crinecerfont placebo for oral capsules

    NEUROCRINE

    Classic Congenital Adrenal Hyperplasia (CAH)

    phase 3 small molecule active

    1 trial

  18. NBI-98854

    NEUROCRINE

    Tardive Dyskinesia

    phase 3 small molecule completed

    6 trials

  19. Placebo

    NEUROCRINE

    Schizophrenia

    phase 3 small molecule completed

    2 trials

  20. Placebo

    NEUROCRINE

    Dyskinesia

    phase 3 small molecule completed

    1 trial

  21. Valbenazine

    NEUROCRINE

    Chorea, Huntington

    phase 3 small molecule active

    3 trials

  22. Valbenazine

    NEUROCRINE

    Tardive Dyskinesia

    phase 3 small molecule completed

    2 trials

  23. Valbenazine, Valbenazine, Placebo for valbenazine capsules

    NEUROCRINE

    Schizophrenia

    phase 3 small molecule active

    1 trial

  24. Chronocort

    NEUROCRINE

    Primary Adrenal Insufficiency

    phase 2 small molecule completed

    1 trial

Drugs (2)

Search drugs →

  1. crinecerfont

    CRENESSITY

    ORAL approved

  2. valbenazine tosylate

    VALBENAZINE TOSYLATE

    ORAL approved

Patents (8)

Search patents →

  1. US 12421193

    GPR52 modulators and methods of use

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12383536

    CRF receptor antagonists and methods of use

    Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12128033

    Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12102637

    Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12083227

    Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11730739

    Treatment of congenital adrenal hyperplasia

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11718618

    Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors

    Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11713324

    Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is NEUROCRINE?

NEUROCRINE (NBIX) is a biotech company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 2 drugs, and 8 patents to this profile..

What pipeline programs does NEUROCRINE sponsor?

We track 24 ClinicalTrials.gov-linked programs for NEUROCRINE, including Chronocort® and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does NEUROCRINE company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.